DDInter438 DDInter1544
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Conivaptan {u} (Compound) resembles {v} (Compound) Tolvaptan
Conivaptan {u} (Compound) resembles {v} (Compound) Deferasirox
Conivaptan {u} (Compound) binds {v} (Gene) AVPR1A
Conivaptan {u} (Compound) is included by {v} (Pharmacologic Class) Antidiuretic Hormone Antagonists
Conivaptan {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Conivaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Conivaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Conivaptan (Compound) resembles Tolvaptan (Compound)
Conivaptan (Compound) resembles Deferasirox (Compound)
Conivaptan (Compound) binds AVPR1A (Gene)
Conivaptan (Compound) is included by Antidiuretic Hormone Antagonists (Pharmacologic Class)
Conivaptan (Compound) causes Feeling abnormal (Side Effect)
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Conivaptan may lead to a major life threatening interaction when taken with Naloxegol